I have SMA. Critics of the $2 million new therapy are missing the point

I have SMA. Critics of the $2 million new therapy are missing the point

I have spinal muscular atrophy. Critics of the $2 million new gene therapy are missing the point

By NATHAN YATES

COURTESY NATHAN YATES

I was perplexed and disappointed that the recent approval of Novartis’ gene therapy Zolgensma was immediately overshadowed by outrage over the drug’s price.

READ MORE